Long Covid

CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

Retrieved on: 
Tuesday, August 3, 2021

This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.

Key Points: 
  • This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.
  • Additionally, ANVISA is reviewing another protocol submitted for a second clinical trial for 316 critically ill COVID-19 patients.
  • After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers

Retrieved on: 
Wednesday, July 21, 2021

This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.

Key Points: 
  • This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.
  • These patients, called COVID-19 "long haulers," report lingering shortness of breath, cough, fatigue, and mental fog for months after recovery, impairing their return to work and everyday life.
  • Even by the lowest health care industry estimates, the magnitude of this secondary health crisis of COVID-19 long haulers will result in millions of affected individuals.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

IncellDx: Two New Studies Offer a First Model for Diagnosing, Monitoring and Treating Long COVID

Retrieved on: 
Wednesday, July 14, 2021

Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

Key Points: 
  • Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.
  • The findings also provide a framework for understanding the cause of, and potential treatment for, long COVID.
  • Long COVID is believed to affect as many as 30 percent of people who have recovered from initial infection with COVID-19.
  • Taken together, findings from these two studies provide an objective and measurable model for understanding whats happening and why long COVID patients continue to experience symptoms long after initial COVID infection, and why those symptoms are so diverse and widespread.

Edward-Elmhurst Health opens Post-COVID Neuro Care Clinic at 11 locations in suburban Chicago

Retrieved on: 
Tuesday, July 13, 2021

To help support the recovery of people experiencing long-term health effects of COVID-19, Edward-Elmhurst Health, a health system in suburban Chicago has established a Post-COVID Neuro Care Clinic.

Key Points: 
  • To help support the recovery of people experiencing long-term health effects of COVID-19, Edward-Elmhurst Health, a health system in suburban Chicago has established a Post-COVID Neuro Care Clinic.
  • "These lingering symptoms can make it difficult to function and can impact your daily life, work, and relationships," says Hurmina Muqtadar, MD, a physician who specializes in neurology and vascular neurology and is a member of the Post-COVID Neuro Care Clinic team.
  • "Our goal is to help ease your symptoms or resolve them so you can put COVID-19 behind you and move forward with life."
  • Commonly reported post-COVID neurological symptoms may include:

Mercaptor Discoveries advances drug candidate to treat brain inflammation in people with long COVID

Retrieved on: 
Wednesday, June 23, 2021

NOVATO, Calif., June 23, 2021 /PRNewswire/ --Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19.

Key Points: 
  • NOVATO, Calif., June 23, 2021 /PRNewswire/ --Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19.
  • Occurring after an acute infection has resolved, the neurological effects of long COVID have been ascribed to insufficiently controlled immune responses and residual virus persisting in the brain.
  • Mercaptor has completed additional efficacy and safety studies for MD-004, their antiepileptic drug candidate designed to halt a seizure before it starts.
  • Mercaptor leverages the chemical environment found in areas of brain disease and damage to complete the synthesis of a drug.

CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

Retrieved on: 
Monday, June 21, 2021

Chris Recknor, M.D., CytoDyns Chief Operating Officer and Head of Clinical Development, commented, We are very pleased with the preliminary results from our long-haulers trial, which showed a greater improvement in the leronlimab patient group over placebo in 18 of 24 COVID-19 symptoms.

Key Points: 
  • Chris Recknor, M.D., CytoDyns Chief Operating Officer and Head of Clinical Development, commented, We are very pleased with the preliminary results from our long-haulers trial, which showed a greater improvement in the leronlimab patient group over placebo in 18 of 24 COVID-19 symptoms.
  • Of the remaining 6 symptoms, sore throat, exertional malaise, anxiety, nausea, and vomiting had no clinically meaningful change.
  • In my opinion, our hypothesis that leronlimab is an immune modulator has received a very positive boost from this trial.
  • This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC.

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Retrieved on: 
Monday, June 21, 2021

Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.

Key Points: 
  • Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.
  • Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 virus from their systems.
  • By improving sleep quality, we believe TNX-102 SL may improve the sleep disturbance of Long COVID and potentially also improve other symptoms of Long COVID.
  • For example, TNX-102 SL showed activity in addressing persistent pain, sleep disturbance and fatigue in our fibromyalgia Phase 3 study.

Nineteen Percent of Asymptomatic COVID-19 Patients Develop Long-Haul COVID

Retrieved on: 
Tuesday, June 15, 2021

Names for such post-COVID conditions include not only long-haul COVID but long COVID, post-COVID syndrome or post-acute sequelae of COVID-19 or of SARS-CoV-2 (PASC).

Key Points: 
  • Names for such post-COVID conditions include not only long-haul COVID but long COVID, post-COVID syndrome or post-acute sequelae of COVID-19 or of SARS-CoV-2 (PASC).
  • The odds of death 30 days or more after initial diagnosis with COVID-19 were 46 times higher for patients who were hospitalized with COVID-19 and discharged than patients who had not been hospitalized.
  • Of COVID-19 patients who were hospitalized and discharged, 0.5 percent died 30 days or more after their initial diagnosis.
  • In addition to asymptomatic patients, those presenting with post-COVID conditions included 27.5 percent of COVID-19 patients who were symptomatic but not hospitalized, 50 percent of hospitalized patients and 23.2 percent of all patients who had COVID-19.